Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Key Highlights
- ➤Prosigna receives Medicare coverage through Palmetto GBA’s MolDX program
- ➤Coverage applies to eligible postmenopausal women with stage I or II ER+ breast cancer
- ➤Coverage effective August 19, 2026, following Prosigna’s June 2026 U.S. launch
- ➤OPTIMA trial found Prosigna-guided treatment could spare chemotherapy for more than two-thirds of clinically high-risk patients
Expert Statements
Marc Stapley, Chief executive officer of Veracyte
“We are pleased that Medicare has taken this significant step to ensure access to Prosigna for physicians and their breast cancer patients to support personalized treatment decisions.”
Marc Stapley, Chief executive officer of Veracyte
“Securing Medicare reimbursement is a key step in establishing broad coverage for Prosigna.”
Marc Stapley, Chief executive officer of Veracyte
“This milestone will help more patients with early-stage breast cancer, and their oncologists, make confident decisions about their treatment, including whether chemotherapy will truly benefit them.”
SOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment submission through Palmetto GBA’s MolDX program. The decision creates a reimbursement path for eligible patients with early-stage breast cancer to receive critical genomic information to help guide their treatment.
Following Prosigna’s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader adoption of the test. Coverage is effective as of August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor positive (ER+) breast cancer who meet the applicable Medicare criteria, including stage I or II disease with 0-3 positive lymph nodes.¹
Get started
Create a free account to read the full story.